Free Trial

Johnson & Johnson $JNJ Stock Holdings Increased by Bessemer Group Inc.

Johnson & Johnson logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Bessemer Group increased its Johnson & Johnson stake by 74.4% in the third quarter, adding 401,649 shares to reach 941,607 shares valued at about $249.3 million.
  • J&J beat quarterly earnings estimates with EPS of $2.59 and revenue of $25.4 billion, up 5.9% year over year. The company declared a quarterly dividend of $1.34 per share.
  • Analysts’ consensus rating is Moderate Buy, with an average price target of $275.92. Two executive vice presidents also reported stock sales during the period.
  • Five stocks we like better than Johnson & Johnson.

Bessemer Group Inc. lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 74.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 941,607 shares of the company's stock after purchasing an additional 401,649 shares during the quarter. Bessemer Group Inc.'s holdings in Johnson & Johnson were worth $249,280,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Outlook Capital Management LLC bought a new stake in Johnson & Johnson in the 2nd quarter valued at about $28,000. Matrix Trust Co raised its position in shares of Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company's stock valued at $38,000 after buying an additional 54 shares in the last quarter. Navigoe LLC boosted its stake in shares of Johnson & Johnson by 60.4% in the third quarter. Navigoe LLC now owns 146 shares of the company's stock valued at $38,000 after buying an additional 55 shares during the period. Montgomery Financial Services LLC bought a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $43,000. Finally, Hanseatic Management Services Inc. acquired a new stake in Johnson & Johnson during the third quarter worth approximately $52,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares of the company's stock, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Elizabeth Forminard sold 13,072 shares of the firm's stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $284.39, for a total value of $3,717,546.08. Following the transaction, the executive vice president owned 16,994 shares of the company's stock, valued at $4,832,923.66. This trade represents a 43.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Citigroup raised their price objective on Johnson & Johnson from $298.00 to $303.00 and gave the stock a "buy" rating in a research note on Monday, October 5th. Bank of America restated a "neutral" rating and issued a $278.00 price target on shares of Johnson & Johnson in a research report on Tuesday, September 29th. Argus set a $300.00 price target on Johnson & Johnson in a research report on Wednesday, July 29th. HSBC boosted their price target on Johnson & Johnson from $290.00 to $320.00 and gave the company a "buy" rating in a research note on Thursday, September 10th. Finally, Evercore set a $300.00 target price on shares of Johnson & Johnson in a report on Tuesday, October 20th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and a consensus price target of $275.92.

Read Our Latest Research Report on JNJ

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $285.78 on Monday. The stock's 50-day moving average is $266.97 and its 200-day moving average is $249.85. Johnson & Johnson has a 1-year low of $193.55 and a 1-year high of $288.11. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. The stock has a market cap of $687.95 billion, a P/E ratio of 43.30, a price-to-earnings-growth ratio of 2.82 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.06. The company had revenue of $25.40 billion for the quarter, compared to analysts' expectations of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. Johnson & Johnson's revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities research analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson's payout ratio is 81.21%.

Latest Johnson & Johnson News

Investors following JNJ have been watching these news items:

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Johnson & Johnson Right Now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines